Neuberger Berman Group LLC Has $182.84 Million Stake in Gilead Sciences, Inc. (GILD)
Neuberger Berman Group LLC lifted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 90.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,583,196 shares of the biopharmaceutical company’s stock after acquiring an additional 1,229,916 shares during the period. Neuberger Berman Group LLC owned approximately 0.20% of Gilead Sciences worth $182,839,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of GILD. Sequoia Financial Advisors LLC boosted its holdings in shares of Gilead Sciences by 10.4% in the first quarter. Sequoia Financial Advisors LLC now owns 80,084 shares of the biopharmaceutical company’s stock worth $5,439,000 after acquiring an additional 7,562 shares during the period. Blue Fin Capital Inc. boosted its holdings in shares of Gilead Sciences by 0.8% in the first quarter. Blue Fin Capital Inc. now owns 7,213 shares of the biopharmaceutical company’s stock worth $489,000 after acquiring an additional 55 shares during the period. Vantage Investment Partners LLC bought a new position in shares of Gilead Sciences in the first quarter worth $9,984,000. Klingenstein Fields & Co. LLC boosted its stake in Gilead Sciences by 4.7% during the first quarter. Klingenstein Fields & Co. LLC now owns 150,173 shares of the biopharmaceutical company’s stock valued at $10,200,000 after buying an additional 6,721 shares during the period. Finally, DT Investment Partners LLC bought a new stake in Gilead Sciences during the first quarter valued at $1,098,000. 74.28% of the stock is owned by hedge funds and other institutional investors.
In other news, insider John C. Martin sold 73,333 shares of the stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $83.11, for a total transaction of $6,094,705.63. Following the transaction, the insider now directly owns 2,996,766 shares in the company, valued at $249,061,222.26. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Robin L. Washington sold 51,820 shares of the stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the transaction, the chief financial officer now owns 43,352 shares in the company, valued at $3,684,920. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 358,486 shares of company stock worth $29,637,678. Insiders own 1.30% of the company’s stock.
Shares of Gilead Sciences, Inc. (GILD) opened at 74.96 on Wednesday. The company has a market capitalization of $97.89 billion, a PE ratio of 8.14 and a beta of 1.14. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $86.27. The firm’s 50-day moving average price is $81.49 and its 200 day moving average price is $73.27.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping the Zacks’ consensus estimate of $2.13 by $0.14. The business had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The company’s quarterly revenue was down 13.2% compared to the same quarter last year. During the same period last year, the company posted $2.75 earnings per share. On average, equities analysts forecast that Gilead Sciences, Inc. will post $8.71 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Stockholders of record on Friday, December 15th will be paid a dividend of $0.52 per share. The ex-dividend date is Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.77%. Gilead Sciences’s dividend payout ratio is presently 23.69%.
Several equities research analysts recently issued reports on GILD shares. BMO Capital Markets reissued a “hold” rating and set a $82.00 price objective on shares of Gilead Sciences in a research note on Friday, October 20th. J P Morgan Chase & Co set a $85.00 price objective on Gilead Sciences and gave the company a “buy” rating in a research note on Wednesday, October 25th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research note on Monday, August 28th. Vetr raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $89.27 price objective for the company in a research note on Wednesday, September 6th. Finally, Morgan Stanley reissued an “equal weight” rating and set a $83.00 price objective (up previously from $77.00) on shares of Gilead Sciences in a research note on Friday, October 6th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Gilead Sciences presently has an average rating of “Buy” and a consensus target price of $85.68.
COPYRIGHT VIOLATION WARNING: “Neuberger Berman Group LLC Has $182.84 Million Stake in Gilead Sciences, Inc. (GILD)” was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://theolympiareport.com/2017/11/01/neuberger-berman-group-llc-has-182-84-million-stake-in-gilead-sciences-inc-gild.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.